We believe the reason for the efficacy of the ADC, even in a low TF expressing tumor cell model, is that in addition to cancer cells, the TF-targeting ADC might also target other TF-positive tumor compartments, such as tumor neovasculature and/or cancer stem cells that selectively express or overexpress TF and could be targeted and eradicated by TF-targeting ICON immunotherapy and fVII-tDT in vitro [15,16] and in vivo [33,37]. This evidence concerns the gene TF and neoplasm.